Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 335

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 335
---
 available to the Company, and even if available, whether it will be on terms acceptable to the Company or in the amounts
required. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and
development programs, which could adversely affect its business prospects, or cease operations.

As
a result of these uncertainties, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would
result if the Company was unable to continue as a going concern.

NOTE
2: SIGNIFICANT ACCOUNTING POLICIES

Basis
of presentation

The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (“US GAAP”).

    F-7

Principles
of consolidation

The
consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have
been eliminated upon consolidation.

Use
of estimates

The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and
circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore,
actual results could differ from those estimates.

Loss
per share

Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.

The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):

SCHEDULE
OF ANTI-DILUTIVE SECURITIES